Solara Acquires J.M.R. Medical
Chula Vista, CA (September 11, 2018) – Solara Medical Supplies (“Solara”), a leading direct-to-patient supplier of advanced diabetic devices, including continuous glucose monitors, insulin pumps and other supplies for the intensively managed diabetic, announced today the acquisition of J.M.R. Medical (“JMR”), an Ohio-based direct-to-patient provider of diabetic testing supplies and a variety of durable medical equipment.
“We are excited to welcome JMR into the Solara family,” said Keith Crawford, CEO of Solara. “The addition of JMR broadens Solara’s reach into the Midwest and builds upon our commitment to providing outstanding service to our patients, suppliers and payors.” Led by Joe and Maria Rogucki, JMR has been serving the Ohio region for over 20 years. Mr. Rogucki, who will remain with Solara, stated, “We are proud of our track record of patient service and look forward to enhancing our offering with the additional expertise, products and patient support that Solara provides.”
Ron Labrum, Chairman of Solara and Operating Partner at Linden Capital Partners, added, “JMR is Solara’s first acquisition following its investment from Linden Capital Partners on May 31, 2018 and represents our strategy to enhance patient service, broaden our national reach and increase value for our manufacturer partners.”
Brown & Fortunato PC served as legal advisor to Solara, a portfolio company of Linden Capital Partners.
About Solara Medical Supplies
Solara Medical Supplies, LLC is a leading direct-to-patient distributor of advanced diabetes therapy products including continuous glucose monitors, durable insulin pumps, and patch insulin pumps. Founded in 2002, Solara is headquartered in Chula Vista, California and operates additional offices in Michigan, Texas, and Alabama. For more information, please visit www.solaramedicalsupplies.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare industry. Linden’s strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.